(VANI) Vivani Medical, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(VANI) Vivani Medical, Inc. Complete Analysis Pack
Vivani Medical Business Model Canvas: Strategic Insights in Biopharma
Unlock a clear, strategic view of Vivani Medical, Inc.’s business model. This concise Business Model Canvas breaks down how the company creates value, builds partnerships, and positions itself in the fast-moving biopharma space. Get the full version to uncover deeper insights and smarter strategic takeaways.
Partnerships
Contract research organizations
External CROs let Vivani Medical, Inc. outsource preclinical tests, study management, data handling, and other regulated work, giving it flexible trial capacity without building a large in-house team. For a clinical-stage company, this is a key lever because CROs can scale programs quickly across GLP and GCP work, which is standard for asset-light biotech development.
Contract manufacturing organizations
Vivani Medical, Inc. uses contract manufacturing organizations to make implantable devices and drug-loaded parts under cGMP quality systems, which is key for scale-up, process validation, and supply continuity. That link is central to moving from prototype to clinical supply, especially since FDA-controlled manufacturing and validated processes are required before human dosing.
Clinical trial hospitals
Clinical trial hospitals and specialty clinics run Vivani Medical, Inc.’s first-in-human and follow-up studies, giving access to patients, surgeons, and procedure support for both drug-implant and visual prosthesis programs. In 2025, these partners let Vivani keep a light fixed-cost base while moving 1st-stage clinical work through expert sites instead of building its own network.
Academic medical centers
Academic medical centers give Vivani Medical access to endocrinology, ophthalmology, and neurology experts, plus translational research support and investigator-led study execution. That matters for device-based programs that need fast proof-of-concept and tight clinical design across small, specialized patient groups.
- Deep specialty expertise
- Stronger translational research
- Faster investigator-led studies
- Better support for device trials
Regulatory and ethics bodies
FDA pathways and institutional review boards are mandatory gatekeepers for Vivani Medical, Inc.; they do not buy products, but they decide when a study can start, expand, or move forward. In the U.S., an IND must clear FDA review before first-in-human dosing, and IRB approval is required at every site before enrollment.
- FDA clears trial start
- IRBs approve site enrollment
- Gatekeepers, not customers
Vivani’s Trial Execution Depends on CROs, CMOs, and Sites
Vivani Medical, Inc. depends on CROs, CMOs, and trial sites to run preclinical work, make cGMP implant parts, and execute first-in-human studies without a heavy fixed-cost base. FDA and IRBs are not customers, but they are the key gatekeepers that must clear each step before enrollment and dosing.
| Partner | Role |
|---|---|
| CROs | Study and data support |
| CMOs | cGMP manufacturing |
| Sites | Patient enrollment |
What is included in the product
Detailed Word Document
A concise, company-specific Business Model Canvas for Vivani Medical’s implantable drug-delivery strategy.
Customizable Excel Spreadsheet
Clarifies Vivani Medical’s business model in one editable view, making strategy review and team alignment fast and simple.
Reference Sources
Provides a credible source trail for Vivani Medical, Inc. that speeds due diligence and supports faster, more confident decisions.
Activities
Miniature implant R&D
Vivani Medical’s core activity is miniature implant R&D: it designs implantable drug delivery systems built for stable, long-duration release, which is the engineering base of its platform. The work supports chronic disease treatment with fewer doses over time, but Vivani Medical has not disclosed 2026/2025 revenue from this activity yet.
Preclinical testing
Vivani Medical, Inc. runs lab and animal studies to test safety, release performance, and device function before human trials. This preclinical work helps refine implant design and dose control, so the company can build the data set needed for IND-enabling review and reduce trial risk.
Clinical development
Clinical development at Vivani Medical, Inc. covers protocol design, enrollment, monitoring, and data analysis for both implantable drug candidates and visual prosthesis programs. Human studies are the key value-creating step before approval, and Vivani’s lead nanoportal implant program has moved through first-in-human testing, where small Phase 1 studies typically run in the tens of patients.
Manufacturing process scale-up
Vivani Medical, Inc. must scale a highly reproducible process for tiny implants and device assemblies, with tight process controls, quality testing, and supply readiness. In 2025, the company was still in development mode and had no commercial product revenue, so scale-up is key to cut technical risk as programs move toward later-stage testing.
- Reproducible implant assembly
- Process control and QC testing
- Supply chain readiness
- Lower technical risk in development
Regulatory and IP management
Vivani Medical, Inc. keeps regulatory submissions and patent work moving in parallel, because device and drug-delivery claims only matter if they clear review and stay protected. In practice, that means defending know-how through the 20-year patent term while pushing each milestone that can support exclusivity, partner interest, and later licensing talks.
- Protect device and delivery IP
- Advance regulatory review milestones
- Preserve exclusivity for partnering
Vivani Medical: Precommercial Nanoportal Development, No 2025 Product Revenue
Vivani Medical, Inc. centers Key Activities on designing nanoportal implants, running preclinical and first-in-human studies, and scaling reproducible micro-assembly and quality control. In 2025, it remained in development mode with no disclosed commercial product revenue.
| Key data | Value |
|---|---|
| 2025 product revenue | None disclosed |
| Development stage | Precommercial |
Full Document Unlocks After Purchase
Business Model Canvas
The Vivani Medical, Inc. Business Model Canvas preview you see here is the exact document you’ll receive after purchase. It’s not a sample or mockup—this is a live snapshot of the final file, complete with the same structure and content. Once you buy, you’ll unlock the full, ready-to-use version in the same format, with no surprises.
Resources
Emeryville headquarters
Vivani Medical is headquartered in Emeryville, California, which anchors its corporate, scientific, and operational leadership in one Bay Area hub. The San Francisco Bay Area supports more than 1,000 life-science companies, giving Vivani Medical close access to biotech talent, research links, and partners.
Implantable device IP
Vivani Medical, Inc. relies on implantable-device IP for its miniature implant and prosthesis designs, which support chronic-disease drug delivery and artificial vision. Patent protection is the moat here: Vivani Medical, Inc. has used this IP base to build 2 core platform bets, NPM-115 and artificial-vision work, in a market where defensible patents can decide long-term value.
Clinical-stage pipeline
Vivani Medical, Inc.'s clinical-stage pipeline spans implant-based drug delivery and implantable visual prosthesis work, so the company is not tied to one readout. In its latest 2025 filings, it still had no commercial product revenue, which makes pipeline progress the main value driver and spreads technical and clinical risk across indications.
Specialized technical team
Vivani Medical, Inc. depends on a small, hard-to-replace team of engineers, scientists, and clinical staff who span biomaterials, drug delivery, neurotechnology, and FDA/regulatory work. In a device-led biotech, that cross-functional bench is the core asset: the company reported 2025 R&D and clinical progress tied to this specialist talent, which is difficult to rebuild if lost.
Cross-functional technical depth
Critical for device and clinical execution
Hard to replace in small biotech
Capital and public-company infrastructure
Vivani Medical, Inc. relies on cash, market access, and SEC reporting systems because it is still a clinical-stage company with no product revenue yet. These public-company resources fund R&D, keep filings current, and support the company’s ability to raise capital for development work.
- Cash funds ongoing trials.
- Market access supports financing.
- SEC systems keep reporting current.
Vivani’s Core Assets: IP, Talent, and Cash
Vivani Medical, Inc.'s key resources are its Emeryville base, its patent-backed implant platform, and its small specialist team in biomaterials, drug delivery, neurotech, and FDA work. In 2025, Vivani Medical, Inc. still had no product revenue, so cash, market access, and SEC reporting systems remained core resources for funding R&D and clinical progress.
| Resource | Why it matters |
|---|---|
| IP and patents | Protects implant platforms |
| Specialist team | Drives R&D and trials |
| Cash and market access | Funds 2025 development |
Value Propositions
Long-acting drug delivery
Vivani Medical, Inc.’s implant platform is built to release drug at a steady rate, which can smooth the peaks and troughs seen with daily pills or shots. For chronic diseases, that steadier exposure can support more consistent treatment and better adherence, a key need in markets already moving toward less-frequent dosing options like weekly GLP-1 therapy.
Lower dosing burden
Vivani Medical, Inc.’s implantable therapy can cut the burden of daily pills or frequent injections, which matters for long-term care. With obesity affecting about 42.4% of U.S. adults and diabetes affecting 38.4 million people, simpler dosing can support better adherence and persistence over time.
Miniature implant format
Vivani Medical’s miniature implant format is built for long wear and repeated use, with a device designed to deliver therapy for up to 6 months in a much smaller footprint than legacy implant systems. That compact size can make insertion simpler and less invasive, which is a clear edge in adherence-driven care.
Artificial vision potential
Vivani Medical, Inc.'s artificial vision work aims to deliver functional visual perception, not just nerve stimulation, for blind patients facing a severe unmet need. The need is large: WHO estimates at least 2.2 billion people live with near or distance vision impairment globally, and current treatment options remain limited for profound blindness.
- Targets usable vision, not signals only
- Addresses severe unmet need
- Limited current alternatives
Two chronic-disease platforms
Vivani Medical, Inc. is building two chronic-disease platforms: long-acting drug delivery and vision restoration. That widens its addressable market beyond one therapy area and puts the Company in both biopharma device and neuromodulation, with a 2-platform model aimed at long-duration care.
- Drug delivery: sustained implant tech
- Vision restoration: neural interface focus
- Two platforms, broader risk spread
Vivani Medical Targets Chronic Care and Vision’s Biggest Gaps
Vivani Medical, Inc. sells long-acting implants that aim to replace daily pills or frequent shots with steadier drug release, which can improve adherence in chronic care. Its vision-restoration work targets a severe unmet need, where WHO says at least 2.2 billion people live with near or distance vision impairment.
| Value proposition | Key data |
|---|---|
| Drug delivery | Up to 6 months dosing |
| Need size | 42.4% obesity, 38.4M diabetes |
| Vision | 2.2B impaired globally |
Customer Relationships
Physician-led treatment pathway
Patients will be routed through specialist physicians, not direct consumer sales, because implantable therapies need clinical judgment, procedure planning, and follow-up care. For Vivani Medical, Inc., physician trust is the adoption gatekeeper: if prescribers do not see clear safety and workflow value, uptake stays slow even when patient demand is there.
Clinical monitoring support
Vivani Medical, Inc.’s implant therapies need regular follow-up visits, safety checks, and outcome tracking so clinicians can confirm device function and patient tolerability. That monitoring also builds the clinical evidence base needed for later commercialization, especially as the Company advances its implant programs through 2025/2026 development milestones.
Surgical and procedural training
Vivani Medical, Inc. is advancing first-generation implantable therapies, so clinician training is a key part of the customer relationship. Procedure support lowers placement errors and site-to-site variation, which helps new centers adopt and manage implantable systems with less friction.
Regulatory-grade evidence sharing
Vivani Medical, Inc. builds customer relationships with regulatory-grade clinical data and clear study reporting, which gives investigators confidence and raises medical community awareness. As a pre-revenue company with no product sales in FY2025, that evidence-first approach also helps frame future reimbursement talks by showing safety, use, and trial discipline.
- Transparent data builds investigator trust.
- Study results grow medical awareness.
- Evidence supports reimbursement prep.
Access and reimbursement support
If Vivani Medical’s implant-based therapies win approval, patients and providers will need coverage checks, prior-auth help, and copay guidance to move from prescription to treatment. In high-cost, procedure-based care, payer and health-system support can cut access friction and speed adoption.
- Coverage navigation for patients
- Prior-auth support for providers
- Payer and hospital onboarding
- Reduces cost-driven drop-off
Trust and Evidence Drive Vivani’s Path to Launch
Vivani Medical, Inc. relies on physician-led relationships, so trust, training, and safety follow-up drive adoption more than direct patient marketing. In FY2025, the Company had no product sales, so customer ties were built through investigators, clinics, and evidence generation rather than commercial service teams.
Because its implant programs are still in development, payer and hospital onboarding will matter once approval nears; prior-auth and coverage support can reduce access friction. Clinical data remains the main relationship tool through 2025/2026 milestones.
| Relationship driver | FY2025/FY2026 signal |
|---|---|
| Physician trust | No product sales in FY2025 |
| Clinical follow-up | Evidence-first development |
| Access support | Coverage prep for launch |
Channels
Clinical trial sites
Vivani Medical, Inc. uses clinical trial sites as the main path to reach patients, with enrollment and first human data flowing through trial centers. In 2025, this network is its first real-world operating layer, since early-stage trials are the only direct patient access channel before any broader market launch.
Specialist physician networks
Vivani Medical, Inc. depends on three key specialist physician networks: endocrinologists, ophthalmologists, and surgical specialists. These clinicians spot eligible patients and, where needed, perform procedures, so their referral patterns will directly shape adoption across the 3 specialty touchpoints.
Hospitals and surgery centers
Hospitals and ambulatory surgery centers are the core channel for Vivani Medical, Inc. device placement and follow-up, because they provide the OR, imaging, recovery, and post-op monitoring these therapies need. The U.S. has about 6,200 hospitals and more than 6,500 ambulatory surgery centers, so this channel gives direct access to the care settings where procedure-based adoption happens.
Strategic commercialization partners
Vivani Medical, Inc. can use out-licensing or co-development partners to reach markets it cannot cover alone, especially for sales, reimbursement, and country rollout. For a clinical-stage company, this channel is a low-capex way to expand reach while keeping the core team focused on R&D.
- Extends sales reach
- Supports reimbursement access
- Adds geographic scale
- Fits a small clinical-stage model
Scientific and investor communications
Vivani Medical, Inc. uses public presentations, peer-reviewed publications, and SEC filings to show clinical and technical progress before launch, which helps investors and clinicians track risk and data readouts. These channels build medical awareness and financial credibility while the Company is still pre-commercial.
- Public talks show pipeline progress
- Publications support scientific trust
- Filings keep investors informed
Vivani’s 2025 Access Path: Trials, Procedures, and Partner Reach
Vivani Medical, Inc. reaches patients mainly through clinical trial sites, specialist referrals, and procedure centers, with partner channels adding reach for launch. In 2025, U.S. access included about 6,200 hospitals and more than 6,500 ambulatory surgery centers, while Vivani Medical, Inc. stayed pre-commercial and relied on publications and SEC filings for visibility.
| Channel | 2025/2026 value | Role |
|---|---|---|
| Clinical sites | First patient access | Enroll, treat, read out |
| Hospitals + ASCs | About 12,700 U.S. sites | Procedure and follow-up |
| Partner deals | Low-capex expansion | Sales, reimbursement, geography |
Customer Segments
Adults with obesity
Adults with obesity are a large target for long-acting metabolic therapy: the World Health Organization says more than 1 billion people live with obesity worldwide, and the U.S. adult prevalence was 40.3% in 2021-2023. This segment can value fewer doses, steadier drug exposure, and simpler adherence in a chronic disease market with very large addressable demand.
Patients with type 2 diabetes
Patients with type 2 diabetes are a large, long-term need segment for Vivani Medical, Inc. The International Diabetes Federation estimated 589 million adults were living with diabetes in 2024, and about 90% had type 2 diabetes, making durable adherence a key pain point for years of treatment. A steady-release implant can help reduce daily dosing burden.
Blind and low-vision patients
Vivani Medical, Inc.’s visual prosthesis program targets blind and low-vision patients, a large group with limited restorative options today; WHO estimates at least 43 million people are blind and 295 million live with moderate to severe vision loss worldwide. The goal is functional artificial vision for patients with severe loss, where unmet need remains high.
Specialist clinicians
Specialist clinicians drive Vivani Medical, Inc. adoption: endocrinologists manage the 589 million adults with diabetes worldwide, while ophthalmologists, retina surgeons, and neurospecialists influence referrals and procedures. Their buy-in matters because diabetes affects 1 in 3 people with diabetic retinopathy, so prescribing and procedure use sit with these clinicians.
- Endocrinologists: prescribing gatekeepers
- Ophthalmologists and retina surgeons: referral and procedure use
- Neurospecialists: niche clinical adoption support
Payers and health systems
Payers and health systems are the economic gatekeepers for Vivani Medical, Inc. They focus on clear clinical benefit, durable outcomes, and lower total cost of care, because coverage rules from health plans, hospital systems, and reimbursement bodies can decide whether the product gets broad commercial access.
- Coverage drives access
- Value must beat cost
- Durability matters most
Vivani Targets Massive Obesity and Diabetes Markets
Vivani Medical, Inc. serves three core customer groups: adults with obesity, patients with type 2 diabetes, and people with severe vision loss. The biggest demand pool is diabetes and obesity, with 589 million adults living with diabetes in 2024 and over 1 billion people with obesity worldwide, so long-acting delivery and low-burden treatment matter.
| Segment | 2024/2025 size | Need |
|---|---|---|
| Obesity | 1B+ global | Fewer doses |
| Type 2 diabetes | 589M diabetes | Adherence |
| Vision loss | 338M+ impaired | Restoration |
Cost Structure
Research and development spend
Research and development is Vivani Medical, Inc.’s biggest cost bucket, and in the latest fiscal year it was about $15 million as the company pushed engineering, formulation, testing, and prototype work. That spend funds both platform expansion and pipeline progress, which is typical for a clinical-stage company.
Clinical trial expenses
Clinical trial expenses cover investigator fees, site payments, monitoring, and data management, and they climb fast as Vivani Medical, Inc. moves from small feasibility studies to larger human trials. Trial work is a major cash use for Vivani Medical, and R&D spending has been a key drain on operating cash in recent fiscal years.
Manufacturing and quality systems
Vivani Medical, Inc. must spend heavily on materials, validation, testing, and batch release because its implant devices need strict quality controls before clinical supply. Manufacturing readiness is a real cost center, but it is the bridge from lab-scale output to future launch volumes.
Regulatory and IP costs
Vivani Medical, Inc. must keep paying for SEC filings, legal compliance, and patent upkeep, so this cost base is recurring, not one-off. In the U.S., patent maintenance fees hit at 3.5, 7.5, and 11.5 years after grant, and core patents can run up to 20 years from filing, so protecting the pipeline stays a long-term expense.
- Recurring filing and compliance spend
- Patent fees due at 3.5, 7.5, 11.5 years
- Protects market position and program timing
General and administrative overhead
Vivani Medical, Inc. carries a fixed general and administrative load from public-company reporting, executive pay, board work, and core corporate functions. For a small biotech with no product sales yet, stock compensation and legal support often take a meaningful share of spend, and this layer is usually less tied to revenue than R&D.
In its latest filings, this overhead is mainly about keeping the public company running, not scaling sales, so costs stay high even before commercialization.
- Fixed public-company costs
- Executive and board support
- Stock comp can be material
- Legal and compliance spend
Vivani Medical’s Costs Are Driven by R&D and Clinical Development
Vivani Medical, Inc. cost structure is driven by R&D, clinical work, and public-company overhead. In the latest fiscal year, R&D was about $15 million, making it the main cash use as the Company funded engineering, formulation, testing, and prototypes.
| Cost bucket | Latest data |
|---|---|
| R&D | About $15 million |
| Clinical trials | High cash use |
| G&A | Fixed public-company costs |
Patent upkeep, SEC reporting, legal work, and stock compensation keep costs recurring even before sales start.
Revenue Streams
Upfront licensing fees
Upfront licensing fees can give Vivani Medical, Inc. cash before commercialization, since device and biotech deals often pay at signing for technology or program rights. Vivani Medical, Inc. is still pre-revenue, so these fees can help fund development without waiting for product sales.
Development milestones
Vivani Medical, Inc. can earn milestone payments when a partner hits clinical, regulatory, or technical gates, so revenue arrives at clear value inflection points instead of only at launch. This model fits platform deals well, especially while Vivani Medical, Inc. remains pre-commercial in 2025 and depends on partnership-linked cash flow rather than product sales.
Royalties on future sales
If partnered assets reach market, Vivani Medical, Inc. can earn sales-based royalties without funding all commercialization costs. In biotech licensing, royalty rates often run in the low-to-mid single digits and can rise with program value, so this stream adds high-margin upside with limited capital risk.
Product sales after approval
Vivani Medical, Inc. could earn direct revenue only if it commercializes its own implants, with sales tied to device uptake and treatment adoption. As a clinical-stage company, this is still a future stream; in its latest reported financials, Vivani Medical, Inc. had no product sales and remained focused on development spending.
- Direct device sales after approval
- Revenue depends on treatment adoption
- No product revenue yet, clinical stage
Research collaborations and grants
Vivani Medical, Inc. can use research collaborations and external grants as non-dilutive funding, so the company can offset early R&D costs before product sales start. This matters in a pre-revenue model: in FY2025, Vivani Medical still relied on capital markets and development funding, while grant-backed work can lower cash burn without issuing more shares.
- Non-dilutive cash, not equity
- Cuts early development spend
- Best before product revenue
Vivani’s FY2025 Revenue Story: Partner Cash, Not Product Sales
Vivani Medical, Inc. is still pre-revenue in FY2025, so revenue streams come mainly from partner cash, not product sales. The main upside is upfront license fees, milestone payments tied to development and regulatory progress, and future royalties if partnered implants reach market.
| Revenue stream | FY2025 status |
|---|---|
| Product sales | None |
| Licensing and milestones | Potential, pre-commercial |
| Royalties | Future upside |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.